Jon-Paul Powers, PhD
Dr. Jon-Paul Powers is a partner and scientific advisor in Gowling WLG's Ottawa office. Working chiefly with the firm's Food & Beverage Group, he advises clients on a range of complex regulatory and compliance matters pertaining to foods, supplemented foods, natural health products and pet supplements. In addition to product and site requirements, J.P. assists clients in need of scientific support pertaining to health claim substantiation and marketing, health risk assessments, product testing and quality management systems.
Prior to joining the firm, J.P. was the owner and president of Split Science Inc., a Canadian scientific and regulatory consultancy specializing in foods, cosmetic and natural health products. He has worked for Canadian manufacturers and distributors of foods and natural health products where he was responsible for all aspects of regulatory affairs and quality management. He also formerly served as a unit head and assessment officer at the Natural Health Products Directorate of Health Canada, where his main responsibilities were the evaluation of clinical trial and product license applications, as well as providing strategic scientific guidance to senior officials.
J.P. is currently a member of the board of directors of the Canadian Health Food Association (CHFA), Canada's largest trade association dedicated to natural health and organic products, and serves as chair of the CHFA Government Relations Council, CHFA Natural Health Products Regulatory Affairs Advisory Council and is a past Chair of the CHFA Food Regulatory Affairs Advisory Council.
J.P. received his PhD in Microbiology from the University of British Columbia and a B.Sc. in Biochemistry from Carleton University. His academic background focused on studying the mechanism of action of cationic, antimicrobial peptides. In addition to a variety of publications and international patents, this work also resulted in the development of a new therapeutic agent that has shown positive preliminary results in Phase II clinical trials.